top of page


HTA Review Options Paper feedback

Submission to Australian Government HTA Review on its options paper for reform of health technology assessment in Australia. Own comments.

February 2024

This submission makes some comments on the Options Paper released by the Australian Government's HTA Review. The Review is examining options for reforming the way the Australian Government uses health technnology assessement to assess the value of medicines and vaccines funded by the Government through programs such as the Pharmaceutical Benefits Scheme and the National Immunisation Program. The submission, independently prepared by Shawview Consulting, is not a comprehensive, complete review of all issues covered in the Options Paper, but rather some initial thoughts on several key issues.

Options paper sub title page.png

Pharmaceutical Manufacturing Industry – India and AMR: Stakeholder Analysis and 
Possible Solutions

Report by Shawview Consulting (UK) and Spans Envirotech (India) with funding from the European Union

November 2023

This report surveys the political economy of antimicrobial resistance (AMR) in the environment in India based on stakeholder surveys and analysis of global and national policies, trends and monitoring solutions. It specifically addresses the contribution of untreated pharmaceutical manufacturing waste to the spread of AMR. The report was prepared by Siddhartha Prakash (Shawview Consulting) and Nitin Verma (Spans Envirotech India) and funded by the European Union. The report was first released in April 2023 at a national stakeholder workshop on AMR in Delhi, India, organised by the EU and Swedish embassies in partnership with the Stockholm International Water Institute, Shawview Consulting, Spans Envirotech and the Responsible Antibiotics Manufacturing Platform (RAMP). The views expressed in this report are the sole responsibility of the authors and do not necessarily represent those of the European Union.

Image AMR India report April 2023.png

Managing, Measuring, Mitigating – Gaining a One Health perspective on removing antimicrobial residues from water

Project initiated by the Minimising AMR Mission, established by CSIRO, and delivered with the support of the Australian Government Department of Agriculture, Fisheries and Forestry, the SAAFE CRC, and AAMRNet.

October 2023

This white paper synthesises the results of discussions held during a workshop entitled Measuring, Managing, Mitigating: gaining a One Health perspective on removing antimicrobial residues from water, that took place on 14 March 2023 at the National Press Club of Australia in Canberra. The workshop was co-convened by CSIRO's Minimising AMR Mission, the Solving Antimicrobial Resistance in Agribusiness, Food and Environments Cooperative 
Research Centre (SAAFE CRC), the Department of Agriculture, Fisheries and Forestry (DAFF) and MTPConnect’s Australian Antimicrobial Resistance Network (AAMRNet). Science and Technology Australia facilitated the discussions.


The future of Aotearoa’s medicines access – fixing the funding model

Report commissioned by Johnson & Johnson New Zealand

August 2023

Report examines current access to medicines in New Zealand, reviews examples of international best practices from other countries, and identifies ways to reform the system of assessing, funding and providing medicines for the New Zealand community.

Image cover medicines funding NZ report.png

Funding innovative medicines

Report for Medicines Australia (contributing author)

May 2023

Report co-authored with Biointelect for Medicines Australia examining reform of Australia's system of funding medicines and vaccines and highlighting the urgent need for Australia to embrace a ‘once-in-a-generation’ opportunity to reform the 75-year-old Pharmaceutical Benefits Scheme.

Image final cover.png

No time left to wait

A discussion paper commissioned by Sanofi Australia)

November 2022

This discussion paper, commissioned by Sanofi Australia, examines the complexity and problems of funding combination treatments for multiple myeloma under Austraila's Pharmaceutical Benefits Scheme. The paper examines current issues and proposes potential strategies to ensure Australian multiple myeloma patients have access to a range of treatments.

Title page.png

Innovation policy instruments (‎non-price)‎ for medical innovation

Report for World Health Organization Europe Office / Oslo Medicines Initiative (contributing author)

September 2022

This Oslo Medicines Initiative technical report presents a broad range of instruments available to national policy-makers in support of innovation for new medicines (‎excluding those focused on price)‎ explores various types of policy instrument, based on reviews of the literature on policies for innovation in the medical and other sectors.

Screenshot cover WHO report.png

Valuing Vaccines: Ensuring Australia's access to vaccines today and tomorrow

Report commissioned by Sanofi

February 2022

Major research report looking at how Australia evaluates, funds and values vaccines, the policy and economic history of Australia's National Immunisation Program, the economic value of current and future vaccines, and lessons learned from the Covid-19 pandemic

Report cover image.png

Submission to the PBAC on the Base Case Discount Rate

Report commissioned by Medicines Australia and prepared with Biointelect.

January 2022

Medicines Australia's submission to Australia's Pharmaceutical Benefits Advisory Committee on the rationale for reducing the base case discount rate used by the PBAC to evaluate medicines and vaccines for public subsidy.

Image discount rate report.png

Getting Australia to the front of the queue

Report prepared for Johnson & Johnson

December 2021

Report prepared on trends in global health, health policy, health technology assessment and Australia's place in the global context

bottom of page